drugset / Trial / NCT00207792

Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation

NCT00207792

Phase 3 Unknown 160 enrolled Centre National de Greffe de Moelle Osseuse
RandomizedParallel-groupOpen-labelTreatment

Summary

The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear. The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor \[G-CSF\] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow transplantation.

Timeline

Start
2005-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic